Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents
Authors:
- 1 January 2014
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (1) , 220-223
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Department of Zhejiang Province (2008F1028, 2012F10005)
- Department of Health of Zhejiang Province (XKQ-010-001)
This publication has 13 references indexed in Scilit:
- Synthesis and structure–activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agentsBioorganic & Medicinal Chemistry Letters, 2012
- Design, Synthesis and Anti-fibrosis Activity Study of N1-Substituted Phenylhydroquinolinone DerivativesMolecules, 2012
- PirfenidoneDrugs, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- The multifaceted role of pirfenidone and its novel targetsFibrogenesis & Tissue Repair, 2010
- Prognostic Factors in Idiopathic Pulmonary FibrosisThe American Journal of the Medical Sciences, 2009
- Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitroInternational Immunopharmacology, 2008
- Incidence and Prevalence of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administrationBiopharmaceutics & Drug Disposition, 2002
- A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational levelEuropean Journal of Pharmacology, 2002